The benefits of continuous epidural infusion of ropivacaine in acute pancreatitis

Evaluating the effectiveness for pain reduction and organ failure improvement of continuous ropivacaine infusion via epidural catheter in acute pancreatitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN82550530

Enrollment

Registered

2023-09-29

Start date

2023-10-01

Completion date

Unknown

Last updated

2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe and predicted severe acute pancreatitis Digestive System

Interventions

VNEPIPAN-HMUIBR968 (The benefits of continuous EPIdural infusion of ropivacaine in acute PANcreatitis) study In the interventional group, thoracic epidural analgesia will be performed using ropivacain

Eligibility

Sex/Gender

All

Age

18 Years to 120 Years

Inclusion criteria

Inclusion criteria: 1. Aged = 18 years. 2. Diagnosis of acute pancreatitis required two of the following three features, as per the revised Atlanta definition: abdominal pain consistent with acute pancreatitis, serum lipase activity at least three times greater than the upper limit of normal, and characteristic findings of acute pancreatitis on contrast-enhanced computed tomography. 3. Onset = 72 h. 4. Pain moderate or severe with visual analog pain scale (VAS) = 4 in consciousness patients or behavioral pain scale (BPS) = 7 in unconsciousness patients. 5. Classification is severe acute pancreatitis (modified Marshall score = 2 on admission) OR predicted severe (at least one of criteria: (1) Ranson's Criteria = 2 points; (2) CRP level > 100 mg/L; (3) Pancreatic necrosis on contrast-enhanced computed tomography.

Exclusion criteria

Exclusion criteria: Patients fulfilling one or more of the following criteria were not included: 1. Prothrombin time < 60%, platelet count < 75 G/L, curative anticoagulant therapy with heparin interrupted for less than 8 h 2. Local infection 3. Failed procedure 4. Anaphylaxis history with ropivacaine, lidocaine, ropivacaine 5. Local anesthetic systemic toxicity history 6. Pregnancy

Design outcomes

Primary

Measure	Time frame
Previous primary outcomes as of 20/04/2026: 1. Pain is measured using the Behavioral Pain Scale (BPS) at admission, 0.5, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, and 120 hours 2. ICU mortality measured using the Sequential Organ Failure Assessment (SOFA) Scores at admission day 1 (D1), day 2 (D2), day 3 (D3), day 4 (D4), day 5 (D5): mean and maximum SOFA score of first 5 days in Center for Critical Care Medicine 3. Gastrointestinal failure during the ICU stay measured using the Gastrointestinal Failure Score (GIF) at admission day 1 (D1), day 2 (D2), day 3 (D3), day 4 (D4), day 5 (D5): mean GIF scores for the first 5 days	—

Measure

Time frame

Previous primary outcomes as of 20/04/2026: 1. Pain is measured using the Behavioral Pain Scale (BPS) at admission, 0.5, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, and 120 hours 2. ICU mortality measured using the Sequential Organ Failure Assessment (SOFA) Scores at admission day 1 (D1), day 2 (D2), day 3 (D3), day 4 (D4), day 5 (D5): mean and maximum SOFA score of first 5 days in Center for Critical Care Medicine 3. Gastrointestinal failure during the ICU stay measured using the Gastrointestinal Failure Score (GIF) at admission day 1 (D1), day 2 (D2), day 3 (D3), day 4 (D4), day 5 (D5): mean GIF scores for the first 5 days

—

Secondary

Measure	Time frame
Previous secondary outcomes as of 20/04/2026: 1. Pain is measured using a Visual Analogue Scale (VAS) at admission, 0.5, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, and 120 hours 2. Mortality rate measured using patient records at day 60 3. Intubation rate measured using patient records at day 30 4. Number of ventilator-free days measured using patient records from randomization to day 30 5. CT Severity Index (CTSI) measured using enhanced CT scanning at 72 hours after Center for Critical Care Medicine admission.	—

Measure

Time frame

Previous secondary outcomes as of 20/04/2026: 1. Pain is measured using a Visual Analogue Scale (VAS) at admission, 0.5, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, and 120 hours 2. Mortality rate measured using patient records at day 60 3. Intubation rate measured using patient records at day 30 4. Number of ventilator-free days measured using patient records from randomization to day 30 5. CT Severity Index (CTSI) measured using enhanced CT scanning at 72 hours after Center for Critical Care Medicine admission.

—

Countries

Viet Nam

Contacts

Public ContactVan Huy Nguyen

nguyenhuy@hmu.edu.vn+84 981899501

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 7, 2026